There are hidden costs in modern cancer treatment that few are willing to talk about, and fewer still have the courage to solve. But for Jim Mullowney, CEO and founder of Pharma-Cycle, ignoring them is not an option. After nearly two decades battling regulatory resistance and institutional silence, he's created a business-ready solution with the potential to transform how chemotherapy waste is handled, not just as a healthcare imperative, but as a smart, scalable business move.
"People ask, 'Who's going to pay for it?'" Mullowney says. "And I always say: it pays for itself."
